University of Alabama in Huntsville

LOUIS
Theses

UAH Electronic Theses and Dissertations

2019

A comparative analysis of tRNA[superscript Ala] production
Brandie Byler

Follow this and additional works at: https://louis.uah.edu/uah-theses

Recommended Citation
Byler, Brandie, "A comparative analysis of tRNA[superscript Ala] production" (2019). Theses. 284.
https://louis.uah.edu/uah-theses/284

This Thesis is brought to you for free and open access by the UAH Electronic Theses and Dissertations at LOUIS. It
has been accepted for inclusion in Theses by an authorized administrator of LOUIS.

ACKNOWLEDGEMENTS

I would like to extend my heartfelt thanks to my advisor, Dr. Robert McFeeters.
His guidance and his genuine care about my well-being and life has been unparalleled in
my academic career. I would also like to thank Dr. William Setzer and Dr. Bernhard
Vogler. Dr. Setzer has continually encouraged me to push myself harder and try things
that seemed out of my reach. Through his instruction and good nature, Dr. Vogler has
challenged me to think outside the box and question myself. I am a better scientist today
than I ever thought I could be because of the patience, care, and kindness of these three
individuals. A sincere thank you also to Dr. David Dignam of the University of Toledo
and Dr. Jack Dunkle of the University of Alabama for the plasmids used in this study and
the starting points for purification protocols.
To my lab mates, thank you for your continued support and for listening to me
complain for two whole years. I am so thankful that I have had the chance to know you
and to grow alongside you.
To my parents, I wouldn’t be here without you. You have set such a good
standard for me on how to be gracious, how to keep going on days when things are
challenging, and how to love one another. You have made me a better person by
teaching me by example.
And to my husband, Kendall, and my two sons, Sean and Seth – to whom I
dedicate this thesis– thank you for believing in me every step of the way. You have been
my inspiration and my driving force. You are my family, and you are my world.
vi

TABLE OF CONTENTS

LIST OF FIGURES ...................................................................................................................... viii
CHAPTER ONE .............................................................................................................................. 1
CHAPTER TWO ........................................................................................................................... 16
2.1 Background .......................................................................................................................... 16
2.2 in vitro Production of tRNAAla – Growth of Bacterial Cultures .......................................... 16
2.3 in vitro DNA Purification Protocol ...................................................................................... 17
2.4 in vitro Restriction Enzyme Digest ...................................................................................... 20
2.5 in vitro Transcription of tRNAAla ......................................................................................... 20
2.6 in vivo Production of tRNAAla – Growth of Bacterial Cultures ........................................... 23
2.7 Purification of in vivo tRNAAla ............................................................................................ 24
2.8 in vivo Production of Alanyl-tRNA synthetase – Growth of Bacterial Cultures ................. 24
2.9 Purification of in vivo ARS875 ............................................................................................ 25
2.10 Aminoacylation .................................................................................................................. 26
CHAPTER THREE ....................................................................................................................... 27
3.1 Background .......................................................................................................................... 27
3.2 in vitro DNA Purification Protocol ...................................................................................... 28
3.3 Eco31I Restriction Enzyme Digest ...................................................................................... 30
3.4 Small Scale in vitro Transcription Optimization ................................................................. 32
3.5 Large Scale in vitro Transcription ....................................................................................... 42
3.6 in vivo Production of tRNAAla .............................................................................................. 46
3.7 in vivo Production of Alanyl-tRNA Synthetase ................................................................... 48
CHAPTER FOUR.......................................................................................................................... 55
4.1 Conclusions .......................................................................................................................... 55
4.2 Future Work ......................................................................................................................... 57
REFERENCES .............................................................................................................................. 61

vii

LIST OF FIGURES

Figure

Page

1.1

History of development of antibiotics

2

1.2

Current antibiotics and their targets

3

1.3

Crystal structure of E. coli Pth1

11

1.4

Structural alignment of E. coli and M. tuberculosis

12

Pth1 crystal structures
1.5

Small angle neutron scattering model of Pth1 in complex

15

in complex with peptidyl-tRNA
3.2.1

Large-scale DNA purification prep results for in vitro

29

production of tRNAAla
3.3.1

BsaI/Eco31I restriction enzyme digest optimization

31

results
3.4.1

Small-scale IVT optimization results for T7 polymerase

34

purification method
3.4.2

Small-scale IVT optimization results for reaction processing 36
time and T7 concentration

3.4.3

Small-scale IVT optimization results for nucleotide and
MgCl2 concentration

viii

38

3.4.4

Small-scale IVT optimization results for GTP and MgCl2

41

concentration
3.5.1

Large-scale in vitro transcription UV shadowing technique

43

3.5.2

Results of large-scale IVT reaction for in vitro production

45

of tRNA

Ala

3.6.1

Acid urea gel results for in vivo production of tRNAAla

47

3.7.1

Chromatograph from Q-Sepharose ion exchange column

49

for in vivo production of Alanyl-tRNA synthetase
3.7.2

SDS-PAGE gel results from ion exchange purification of

50

Alanyl-tRNA synthetase
3.7.3

Chromatograph from size exclusion chromatography column 52
for purification of Alanyl-tRNA synthetase

3.7.4

SDS-PAGE gel results from size exclusion chromatography 53
for Alanyl-tRNA synthetase purification

ix

CHAPTER ONE

INTRODUCTION

The development of antibiotics was extremely important for modern science and
medicine. It allowed for the ability to treat previously detrimental diseases and
conditions. Though penicillin was first discovered by Fleming in 1928 [1], the first
antibiotic on the market was a sulfonamide in the 1930s, developed by German
biochemist Gerhard Domagk [2]. After the release of the first penicillin to the market in
1942, the “Golden Age” of antibiotics began. Though many classes of antibiotics have
been introduced to modern medicine, the majority of these drugs came onto the market
during this “Golden Age,” between 1940 and 1962 [3]. The timeline for discovery of
antibiotic drugs is shown in Figure 1.1.
Though hundreds of antibiotics exist today to treat bacterial infections, most of
these antibiotics are comprised of seven major classes: Penicillins, cephalosporins,
macrolides, fluoroquinolones, sulfonamides, tetracyclines, and aminoglycosides. The
mechanism of action for each of these classes can exhibit either bacteriostatic or
bactericidal activity. An overview of the particular mechanisms of action for the major
antibiotic classes is shown in Figure 1.2.
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Figure 1.1 This figure provides a timeline of discovery for antibiotic drugs. All dates
provided in this timeline represent the dates of initial discovery or patent. Of note is the
presence of the discovery void, occurring after 1987 [4].
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Amikacin

Figure 1.2 This is a visual representation of the current treatments for bacterial infections
and their targets [5].
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Both penicillins and cephalosporins are β-lactam antibiotics which employ
Penicillin Binding Proteins (PBPs) to inhibit enzyme activity needed for cross-linking of
peptidoglycans in the cell wall [6]. This causes the cell wall to weaken, and as the
osmotic gradient cannot be maintained, cell lysis occurs [7].
Macrolides and tetracyclines exhibit bacteriostatic activity, inhibiting protein
synthesis by binding reversibly to the ribosome [8]. The binding of macrolides to the P
site of the 50s subunit prevents the action of peptidyltransferase, whereas the binding of
tetracyclines to the 30s ribosomal subunit prevents aminoacyl tRNA from binding to the
A site [9, 10].
Aminoglycosides also inhibit protein synthesis, but do so through bactericidal
activity, as the binding of this drug to the membrane-associated ribosome affects
translational proofreading and leads to inaccurately translated protein products [11].
Some of these proteins are incorporated into the cell membrane, which causes changes in
permeability, as well as loss of functional integrity [12, 13].
Fluoroquinolones are a broad-spectrum class of bactericidal antibiotics that affect
DNA replication. These drugs inhibit the activity of DNA gyrase or topoisomerase IV.
An additional target of quinolone-based drugs is topoisomerase II [2, 14]. Lastly, the
sulfonamide class of antibiotics functions as a bacteriostatic drug, inhibiting growth and
multiplication of bacteria through the inhibition of the dihydropteroate synthase enzyme,
which is involved in folate synthesis [15, 16].
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Unfortunately, there is a growing problem associated with antibiotic use and that
is the increasing rise of antibiotic resistance. The production of β-lactamases, enzymes
which break down the β-lactam ring present in both penicillins and cephalosporins,
allows for bacteria to become resistant to these classes of drugs [17, 18]. Modified
penicillins have been produced to combat this resistance; however, mutations in the
bacterial genome have allowed for production of PBPs with reduced affinity to these
drugs or even acquisition of β-lactam-insensitive PBPs [19].
Regarding the classes that affect protein synthesis, bacterial resistance to
macrolides primarily occurs through post-transcriptional methylation of the 23s bacterial
ribosomal RNA. This resistance can either occur as plasmid-mediated or chromosomal
but are most commonly catalyzed by an enzyme which methylates an adenine residue in
in the ribosomal subunit [20]. Resistance to macrolides can also occur via the use of
efflux mechanisms encoded by the mef genes [17, 21] which effectively force the
antibiotic out of the bacterial cell. Lastly, bacterial resistance to macrolides can occur via
inactivation of the drug, whether by use of an esterase, nucleotidyltransferase, or
hydrolase [22–24].
The widespread use of tetracyclines has contributed to bacterial resistance.
Because these drugs are administered orally, the bacterial population of the intestines can
develop resistance to the drugs due to the fact that not all of the drug absorbs into the
gastrointestinal tract [25]. This not only leads to the development of resistance in the
present bacteria, but also potential overgrowth of the now-resistant organisms. The
mechanism with which these bacterial develop resistance is primarily through acquisition
of new genes which codes for proteins which share homology with EF-G and EF-Tu and
5

shield the ribosome from the mechanism of action of tetracyclines [17]. Decreased
permeability of the outer cellular membrane leads to another path of tetracycline
resistance, as this allows the bacterial cell to effectively limit the influx of the antibiotic
[26], and porin mutations through amino acid substitution in some bacterial strains have
been shown to be connected to tetracycline resistance [27]. Other basic mechanisms of
resistance, such as regulation of drug efflux and enzymatic inactivation of tetracycline are
also areas for concern [25, 28].
Aminoglycoside resistance commonly occurs via three different mechanisms [29]:
A chromosomally mediated resistance leading to reduced uptake or decreased cell
permeability, mutations leading to the alteration of ribosome binding sites, or enzymemediated resistance due to mutation of genes which encode enzymes that participate in
cellular respiration.

Drug inactivation is also a risk factor for resistance to

aminoglycosides, as enzymatic modification of the antibiotic through acetylation,
phosphorylation, or adenylation can lead to the prevention of these drugs to their
ribosomal binding target [30]. Not only can the drug itself be modified, but the
ribosomal binding site itself can undergo methylation to reduce the binding affinity [31].
Though it has been shown that there are few bacterial efflux systems which affect
aminoglycosides, some particular species which possess multidrug efflux systems have
exhibited the ability to confer resistance to aminoglycosides via this method [32, 33].
Resistance to fluoroquinolone drugs can occur rapidly, even during the course of
treatment. Bacterial resistance to these drugs can occur via three different mechanisms
[34, 35]: efflux pumps can decrease the intracellular quinolone concentration; plasmidmediated resistance genes in Gram negative bacteria can mutate to produce gyrase6

binding proteins, which protect from the action of quinolones; or mutations can occur at
key sites in either DNA gyrase or topoisomerase IV to decrease binding affinity of the
drug. Though a reduction in porins can lead to decreased uptake of fluoroquinolones, this
mechanism accounts for very little resistance to the drug [36]. As with other classes of
antibiotics, the resistance developed through efflux pumps involves the active removal of
the antibiotic through the use of a cytosolic pump system. This cytosolic pump is linked
to an outer membrane protein via a membrane fusion protein [35], the energy for which is
supplied by the proton gradient [37]. Plasmid-mediated resistance occurs via production
of the pentapeptide Qnr [38] which binds to gyrase and protects it from the action of
fluoroquinolones through the potential alteration of the drug-binding pocket [39].
Binding affinity of fluoroquinolones can also be affected by mutations in the targets of
the antibiotic, DNA gyrase or topoisomerase IV. These mutations in DNA gyrase occur
within the N-terminus in a region called the quinolone resistance-determining region, and
frequently appear near the active site of DNA gyrase [40], which allows for reduced
binding of the drugs. Though topoisomerase IV is generally considered a secondary
target for this class of antibiotics, mutations can occur in topoisomerase IV primarily
when the sensitivity of DNA gyrase has been reduced [41, 42]. These mutations occur in
the parC gene.
As sulfonamides were the first class of antibiotics developed, and the class has
had widespread use for a multitude of bacterial infections, resistance has become
commonplace for many bacterial species. As mentioned previously, this class of
antibiotics targets the enzyme dihydropteroate synthase, which is involved in folate
synthesis. As a result of regular exposure to sulfonamides, mutations in the
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dihydropteroate synthase enzyme have occurred, allowing the enzyme to function
normally, even in the presence of sulfonamides [43]. Resistance to this class of
antibiotics can occur via either chromosomal or plasmid-mediated resistance.
Chromosomal resistance generally occurs via point mutations in conserved regions of the
DHPS gene as seen in E. coli, or as genetic insertions in the DHPS gene as demonstrated
by sulfonamide-resistant strains of N. meningitidis and S. pneumoniae [44]. These
mutations effectively decrease the binding affinity for the antibiotic class. Plasmid-borne
resistance to sulfonamide drugs involves the sul1 and sul2 genes, and results in drugresistant variants of the DHPS enzymes [45].
Because of the rise of resistance to all major classes of antibiotics, there has been
an increase in the number of bacterial infections that do not respond to treatment.
According to a 2018 report by the Centers for Disease Control, each year in the United
States there are at least 2 million people that contract an antibiotic-resistant infection, and
at least 23,000 of those infections result in death. Notably, in the 2013 Antibiotic
Resistance Threats in the United States report from the CDC, the top 18 antibioticresistant threats were identified as public health concerns [46]. Included in these threats
are methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant
Enterococcus (VRE).
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Staphylococcus aureus developed resistance to penicillin in the late 1940s
because of overuse and misuse of the drug. As a result of this resistance, methicillin was
introduced as a modified version of penicillin to combat these infections [47]. However,
some S. aureus strains are now resistant to methicillin and to the entire subsection of βlactam antibiotics. Approximately one-third of people have S. aureus on their body at
any given point, generally found in the nose or on the skin, and about 1% of this is
methicillin-resistant, according to the Centers for Disease Control and Prevention. There
has been a rise in the amount of hospital-associated MRSA (HA-MRSA) infections over
the past decade, primarily due to the increase in number of both elderly and
immunocompromised patients [48, 49]. Advancements in modern medicine have
allowed for an increase in the invasiveness of medical procedures, and this has also
contributed to the progression of the rate of infection. In addition, though MRSA was
primarily a nosocomial infection in the past, new strains of MRSA have emerged which
can infect those that are otherwise healthy. This is called community-associated MRSA
(CA-MRSA). Typically, CA-MRSA infections present initially as soft tissue or skin
infections, but these infections can progress into conditions that are potentially more lifethreatening [50, 51]. In 2011, MRSA was responsible for 80,000 infections and 11,000
deaths [52].
Vancomycin-resistant enterococcus is a large threat to public health. Enterococci
is a bacterial species that is generally found in both the digestive tract and the female
genital tract [53]. Infections from enterococci species most commonly are nosocomial in
nature, and these types of infections are among the most common of those that are
hospital-acquired. While the chance of an epidemic arising because of enterococci
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species is not likely, there is still a concern associated with these infections, as infections
that result in disease can be fatal. Interestingly, enterococci have been shown to evade
several forms of antibiotic treatments, most notably vancomycin, which is considered a
last resort medication for most bacterial infections [54]. Not only have enterococci
species been shown to exhibit resistance against the major antibiotic classes, but
remarkably, vancomycin-resistant Enterococcus has been shown to be able to pass
resistance genes to other pathogens via conjugative transfer [55, 56]. As a result, there
have been reports of vancomycin-resistant Staphylococcus aureus (VRSA).
As antibiotic resistance seems to be an issue that is only becoming more prevalent
and concerning, it is of utmost importance that development of new drugs be achieved.
There has not been development of a new class of antibiotics in over 30 years, a crisis
known as the discovery gap [4]. To combat the rise of antibiotic resistance, it is
necessary to determine potential classes of antibiotics with novel targets and mechanisms
of action.
One such potential target is the bacterial enzyme peptidyl-tRNA hydrolase 1.
This enzyme is 21 kDa and monomeric, consisting of a single α/β globular domain with
191-194 residues [57]. At 41 Å in length and 35 Å in width, the compact globular
molecule contains six surrounding α-helices and seven β-strands, which comprise the
core of the molecule [58]. Figure 1.3 shows the detailed crystal structure of E. coli Pth1.
There are three active site residues which are conserved in all bacterial species, Asn10,
His20, and Asp93, as numbered in E. coli [59]. Notably, the Pth1 enzyme has been
shown to have a high degree of sequence similarity between species. Figure 1.4
demonstrates the structure similarity between Pth1 of different bacterial species.
10

Figure 1.3 Detailed crystal structure of E. coli Pth1 enzyme determined by x-ray
crystallography (PDB ID: 2PTH). The central mixed β-sheet core surrounded by αhelices can be clearly seen in this crystal structure. This structure was generated using
MOE 2019.01.
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Figure 1.4 Structural alignment of E. coli Pth1 (dark purple, PDB ID: 2PTH) and M.
tuberculosis Pth1 (cyan, PDB ID: 2Z2I). The side chains of catalytically essential
residue His20 and the corresponding His22 residue for M. tuberculosis are shown
(arrow). This structural alignment was generated via MOE 2019.01.
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Peptidyl-tRNA hydrolase 1 (Pth1) performs a very specific action.
Approximately 10% of the time during translation, the ribosome stalls [60]. When
stalled, the cell has rescue mechanisms that can be employed in order to maintain the
ability of the cell to continue protein synthesis [61, 62]. If these rescue mechanisms fail,
the ribosome disassembles via the Ribosome Recycling Factor and Elongation Factor G
and the tRNA molecule attached to the growing nascent peptide chain (peptidyl-tRNA) is
released into the cell [63]. Pth1 is a hydrolase and is responsible for cleaving the ester
bond between the tRNA molecules and the attached growing peptide chain to allow for
the tRNA molecules to be recycled and reused for further protein translation. Without
the ability of Pth1 to cleave this bond and recycle tRNA, an accumulation of peptidyltRNA would occur in the cell, leading to cell death [58]. Thus, Pth1 is essential in
bacteria.
Though Pth1 is ubiquitous in bacterial species and is the only mechanism with
which they can recycle tRNA molecules, there are other mechanisms in eukaryotes that
perform this action [64–66]. Importantly, the Pth systems found in eukaryotic systems do
not share homology with that of bacterial Pth1. The only exception to this pertains to
very few non-pathogenic bacterial strains that have acquired Pth2, the enzyme present in
eukaryotic organisms [67]. This lack of homology coupled with the essential function of
the enzyme in bacteria and its high degree of structural similarity between species makes
Pth1 a novel target for broad-spectrum antibacterial inhibition and potentially a candidate
for a new class of antibiotics [68].
Though high-resolution crystal structures have been solved for many bacterial
Pth1s [69–72], there has yet to be a high-resolution crystal structure for Pth1 in complex
13

with peptidyl-tRNA. Small angle neutron scattering has been used to determine a lowresolution shape determination of the Pth1:peptidyl-tRNA complex using bulk peptidyltRNA [73] (shown in Figure 1.5); however, a high-resolution structure is needed in order
to completely evaluate the binding interactions at play for potential inhibitor design. As
tRNA molecules exhibit variation in their structure at the anticodon region and, more
importantly in this case, the acceptor stem, an ideal high-resolution crystal structure
would be one containing an amino acid-specific peptidyl-tRNA molecule in complex
with Pth1. If this could be achieved, it would be possible to fully elucidate the binding
interactions of the enzyme-substrate complex. As of this point, strides have been made to
better understand the binding interactions of Pth1 in complex with peptidyl-tRNA via
partial substrate structures [74] and crystal structures studying the interactions at the TψC
loop [75]; however, structures and interactions associated with the TψC loop provide
unreliable data due to the distance of the proposed binding site from the known 3’ active
site of the molecule.
It is the goal of this research to generate tRNAAla by in vitro and in vivo
production. A comparison of the methods involved, as well as the yield and efficiency of
each process, allows for a better understanding of the necessary requirements for
production of amino acid-specific tRNA molecules and their ability to be aminoacylated
for further study with Pth1. Production of tRNAAla is the first step in making a specific
peptide peptidyl-tRNA, aimed at obtaining a high-resolution crystal structure of the
Pth1:peptidyl-tRNA complex. A high-resolution structure of the bound state is essential
to advancing Pth1 as a novel antibacterial target.
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Figure 1.5 Small angle neutron scattering model of Pth1 in complex with peptidyl-tRNA.
The blue structure represented is tRNA. The red, globular structure is the Pth1 enzyme.
The gold spheres are representative of the calculated shape of the overall Pth1:peptidyltRNA complex [73]. The lower insets show the separate parts of the image.
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CHAPTER TWO

METHODS

2.1 Background
In order to successfully compare the production of tRNAAla, both in vitro and in
vivo protocols were performed. The in vitro method of production consisted of a largescale DNA purification protocol, a restriction enzyme digest, and in vitro transcription
using T7 polymerase, using a plasmid and protocol adapted from Dr. Jack Dunkle [76].
Next, in vivo production of tRNAAla and alanyl-tRNA synthetase was performed, utilizing
purification via FPLC. The plasmids and protocols for the in vivo production were
obtained from Dr. David Dignam [77]. To test the activity of the produced enzyme in
conjunction with the produced tRNAAla, an aminoacylation reaction was performed [78].

2.2 in vitro Production of tRNAAla – Growth of Bacterial Cultures
Using the plasmid from Dr. Dunkle’s lab at the University of Alabama, E. coli
DH5α cells were transformed and grown on a Luria-Bertani (LB) agar plate containing
carbenicillin. A 3 mL starter culture using LB broth and 30 μg/mL of carbenicillin was
prepared using a single colony from the LB agar plate. This culture was then grown at
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37 °C for 5 hours in the incubator. Once the culture had been grown, the culture was
transferred to a 4 L flask with 1 L of LB broth and carbenicillin to allow for a 1:4
aeration rate. The 1 L culture was allowed to grow overnight for 16 hours, after which it
was harvested via centrifugation for 20 minutes at 2,000 x g. The supernatant was then
discarded, and the cell pellet was redissolved in 30 mL of LB broth, placed in a 50 mL
conical tube and centrifuged at 20,000 x g for 10 minutes. After discarding the
supernatant, the cell pellet was stored at -80 °C until purification.

2.3 in vitro DNA Purification Protocol
The cell pellet was resuspended in 10 mL of Solution 1, which contained 25 mM
Tris-HCl, pH 8.0; 10 mM ethylenediaminetetraacetic acid (EDTA); and 5 mM glucose.
To perform cell lysis, 20 mL of Solution 2 (2% SDS; 200 mM NaOH) was added to the
resuspended mixture, inverting the tube several times to thoroughly mix, after which the
tube was allowed to stand for 3 minutes. A total of 15 mL of 3 M KOAc, pH 4.5, was
added to the lysed cells in order to neutralize the lysis, and the tube was inverted to mix.
Following mixture, the cells were then centrifuged for 15 minutes at 20,000 x g. After
centrifugation, the supernatant containing DNA and RNA was filtered through
cheesecloth into a 250 mL beaker. The cell debris pellet was discarded.
An ethanol precipitation was performed in order to facilitate the isolation of DNA
and RNA from the supernatant. This was done by the addition of 110 mL of 100%
ethanol to the 25 mL of supernatant for a final ethanol percentage of approximately 80%.
The mixture was incubated on ice for 10 minutes, after which it was divided into 50 mL
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conical tubes and centrifuged for 10 minutes at 17,000 x g at 4 °C. The supernatant was
discarded, and the pellet was allowed to dry at room temperature for 60 minutes.
After drying the pellet, it was resuspended in 6 mL of TE buffer (10 mM TrisHCl, pH 7.5; 1 mM EDTA). To precipitate the RNA, 3 mL of 7.5 M NH4OAc was
added. The solution was thoroughly mixed and allowed to incubate for 30 minutes on
ice. After incubation, the mixture was centrifuged at 20,000 x g for 15 minutes.
The resulting supernatant was then transferred to a new 50 mL conical tube, and
20 mL of 100% ethanol was added to the 6 mL of DNA for precipitation. The mixture
was incubated overnight at -20 °C, forming a clearly visible white precipitate, and then
centrifuged for 15 minutes at 17,000 x g.
The supernatant was discarded, and the pellet was resuspended in 3 mL of TE
buffer. This suspension was then transferred to a 15 mL conical tube and DNA
extraction from protein was performed via a phenol: chloroform: isoamyl alcohol
(25:24:1) extraction. An equal amount of phenol: chloroform: isoamyl alcohol was
added to the 15 mL conical tube and the tube was vortexed to allow for thorough mixing.
The tube was then centrifuged at 2,000 x g for 5 minutes. The aqueous layer was
transferred to a new 15 mL conical tube and an equal volume of chloroform was added to
remove excess phenol. The tube was inverted to mix, and then centrifuged again at 2,000
x g for 5 minutes. After centrifugation, the aqueous layer was again transferred to a fresh
50 mL conical tube.
In order to precipitate out the DNA, two volumes of 0.3 M NaOAc, pH 5.2, in
ethanol was added. This mixture was incubated on ice for 30 minutes, after which it was
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centrifuged for 10 minutes at 17,000 x g. The supernatant was discarded, and the pellet
was washed with 1 mL of 70% ethanol. The tube was then centrifuged again for 5
minutes at 17,000 x g. The ethanol was removed, and the pellet was thoroughly dried
and then redissolved in 300 μL of TE buffer.
Finally, a polyethylene glycol (PEG) precipitation was performed to isolate the
DNA from the suspension. A volume of 120 μL of 5 M NaCl and 750 μL of 13% PEG
8000 was added to the suspension. This mixture was incubated for 30 minutes at room
temperature. The mixture was then centrifuged for 10 minutes at 20,000 x g at 4 °C and
the supernatant was removed. This process was repeated twice in order to minimize
small molecule contamination. The pellet was then washed with 1 mL of 70% ethanol
and centrifuged for 5 minutes at 6,000 x g. The ethanol was then removed, and the pellet
was dried thoroughly, after which it was redissolved in 1 mL of TE buffer and stored at
-20 °C. Verification of production of the 2.7 kb plasmid was obtained via 1.5% agarose
DNA gel using 1x Tris-acetate-EDTA (TAE) buffer and ethidium bromide and
subsequent visualization. Quantification of the plasmid DNA was performed via UV
absorbance, A260/A280.
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2.4 in vitro Restriction Enzyme Digest
Linearization of the plasmid DNA template was performed using a restriction
enzyme digest with BsaI/Eco31I. Optimization was done to determine the efficiency of
the fast digest versus high fidelity enzyme. According to the concentration of purified
plasmid DNA determined by UV absorbance, a volume (~40 μL) of plasmid DNA was
used to effectuate a total reaction concentration of 200 μg of DNA per 200 μL reaction.
This was combined in an Eppendorf tube with 20 μL of Cut Smart buffer, 120 μL of
deionized water (ddH2O), and 20 μL of Eco31I fast digest restriction enzyme, with the
restriction enzyme being added to the reaction mixture last. The reaction was allowed to
proceed in an incubator at 37 °C for 17 hours.
After the allotted time, the reaction mixture was removed from the incubator and
analyzed via 1.5% agarose DNA gel with 1x TAE buffer and ethidium bromide to verify
that the plasmid DNA had been completely cleaved with resulting 1.2 kb and 1.4 kb
bands. The digest product was then stored at -20 °C for use in in vitro transcription.

2.5 in vitro Transcription of tRNAAla
Small scale in vitro transcription (IVT) was first performed in order to optimize
the conditions needed for maximum efficiency in a large-scale reaction. Stock solutions
were prepared for the reagents used in the IVT reaction. These stock solutions consisted
of 1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES-KOH), pH 7.5; 1 M
MgCl2; 200 mM spermidine; 1 M dithiothreitol (DTT); 10 mM each of ATP, GTP, CTP,
UTP.
20

T7 polymerase purified by Ni2+ affinity column was utilized in the reaction. This
purified T7 polymerase was split into three equal parts: one part was further purified via
Q-column ion exchange chromatography; one part was further purified using size
exclusion chromatography; and one part did not undergo further purification. All three
means of purification were then compared for efficiency in production of tRNAAla as
follows. For a total reaction volume of 100 μL, 20 μL of HEPES-KOH (200 mM final
concentration), 2.8 μL of MgCl2 (28 mM), 1 μL of spermidine (2 mM), 4 μL of DTT (40
mM), 15 μL of each rNTP (6 mM each), 10 μL of DNA template, and 1.7 μL of ddH2O
was added to an Eppendorf tube, followed by 0.5 μL of T7 polymerase. Three separate
reactions, one for each DNA purification, were performed in order to evaluate the
effectiveness of the polymerase based on purification method. These tubes were
incubated at 37 °C for 5 hours and immediately processed for analysis.
To analyze the small scale IVT reactions, a 6% urea-PAGE gel was run with 1x
Tris-borate-EDTA (TBE) running buffer. Samples were prepared using 6 μL of IVT
reaction, 3 μL of ddH2O, and 9 μL of formamide dye. The gel was pre-run at 200 V for
15 minutes and samples were heated at 90 °C for 1 minute and then snap cooled on ice.
The samples were then loaded onto the gel and the gel was run at 200 V for 45 minutes.
The gel was then stained with SYBR Gold in a 5 μL dye to 50 mL 1x TBE ratio for 15
minutes.
After optimization of T7 polymerase purification methods, further optimization
was performed to determine the most efficient concentration of T7 polymerase, as well as
evaluate the reaction processing time. Separate small scale IVT reactions were run in
enzyme concentrations of 0.5 μL, 1 μL, and 2 μL for processing times of 3, 4, and 5
21

hours. At each time point, 6 μL of the IVT reaction was sampled to analyze via 6% ureaPAGE gel as above.
Small scale IVT reactions were then performed to determine if increased
concentration of nucleotides and MgCl2 would affect production of tRNAAla. Nucleotide
concentrations were tested at 4.5 mM, 6 mM, 7.5 mM, and 9 mM. MgCl2 concentrations
were evaluated at 20 mM, 28 mM, 36 mM, and 42 mM. All other reaction concentrations
remained unchanged. The reactions were incubated at 37 °C for a total of 5 hours, after
which they were processed via 6% urea-PAGE gel and stained with SYBR Gold.
Optimization was next performed in order to test if an increase in GTP
concentration alone would effectuate increased production of tRNAAla [79]. Small scale
IVT reactions were run with GTP concentrations of 9 mM and 12 mM for four total
reactions, two with increased MgCl2 concentrations of 42 mM and two with standard
protocol concentrations of 28 mM. These reactions were incubated at 37 °C for 5 hours
and then processed via urea-PAGE gel.
As optimization of the small scale IVT was completed, a large-scale IVT reaction
was then performed. In a total reaction volume of 1 mL, 200 mM of HEPES-KOH, pH
7.5; 21 mM MgCl2, 2 mM spermidine, 40 mM DTT, 4.5 mM ATP, CTP, and UTP; 12
mM GTP; 100 μL of DNA template; and 129 μL of ddH2O were combined. To this
mixture, 20 μL of T7 polymerase was added. The large scale IVT reaction was incubated
at 37 °C for 5 hours.
To process the large-scale reaction, four 6% urea-PAGE mini-gels were prepared.
The large-scale reaction mixtures were combined with formamide dye in a 1:1 ratio. The
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samples were heated at 95 °C for 1 minute and then placed on ice. The urea-PAGE gels
were pre-run at 200 V for 15 minutes, after which the wells were flushed and loaded with
250 μL of IVT reaction per each gel. The urea gels were then run at 200 V for 45
minutes.
UV shadowing excision was used to isolate the produced tRNAAla from the minigels. The gels were placed on a TLC plate and UV light was used to locate the tRNAAla.
The produced tRNAAla was present between the two separate bands of dye and presented
as a shadow under UV light. The gel slices were excised from each gel and then placed
in a 50 mL conical tube with 2 mL of 1x TBE buffer and allowed to soak overnight.
Samples of the buffer were taken after 1, 2, and 3 days of passive elution, ensuring to
change the buffer solution after each day. Results were analyzed via 6% urea-PAGE gel
and SYBR Gold stain.

2.6 in vivo Production of tRNAAla – Growth of Bacterial Cultures
Using the PWW-ectRNAAla plasmid, MRE600 cells were transformed and plated
on LB agar plates containing carbenicillin. Using a single colony from this plate, a
starter culture was prepared consisting of 30 mL of 2X LB broth and 30 μg/mL
carbenicillin. This culture was grown at 37 °C overnight and then transferred to 1 L of
2X LB broth and carbenicillin in a 4 L flask to allow for a 1:4 aeration rate. These cells
were grown until OD600 0.4 was reached, after which they were induced with 0.2 mM
Isopropyl β-D-1-thiogalactopyranoside (IPTG) for expression. The culture was then
allowed to grow for an additional 20 hours and harvested via centrifugation.
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2.7 Purification of in vivo tRNAAla
The cell pellet was resuspended in 5 volumes of 0.1 M NaOAc, pH 4.5, and 1 mM
EDTA. The mixture was then extracted twice with an equal volume of phenol for 30
minutes, after which it was centrifuged at 2,000 x g for 10 minutes. The aqueous layer
was then removed and extracted with an equal volume of chloroform for 30 minutes,
after which it was centrifuged at 2,000 x g for 10 minutes. The aqueous layer was then
placed in a 50 mL conical tube and precipitated with 2.5 volumes of 100% ethanol at
-20 °C. The precipitate was then resuspended in ddH2O and analyzed via 6% acid urea
gel, using controls of bulk peptidyl-tRNA and cleaved peptidyl-tRNA to evaluate for the
production of tRNAAla.

2.8 in vivo Production of Alanyl-tRNA synthetase – Growth of Bacterial Cultures
Using the plasmid from Dr. Dignam’s lab for production of wildtype alanyl-tRNA
synthetase (ARS875) in vector pET12a, E. coli BL21 cells were transformed and plated
on an LB agar plate containing carbenicillin. A single colony from this plate was used to
produce a starter culture containing 3 mL of LB media and 30 μg/mL carbenicillin. After
growth for 5 hours, the culture was then transferred to a 4 L flask with 1 L of LB media
and carbenicillin to allow for a 1:4 aeration rate. This culture was grown at 37 °C until it
reached an OD600 of 0.5, after which it was induced with 0.2 mM of IPTG for protein
expression. The cells were then allowed to grow for 4 more hours and then harvested via
centrifugation. The cell pellet was stored at -80 °C until purification.
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2.9 Purification of in vivo ARS875
The cell pellet was resuspended in 6 volumes of buffer containing 50 mM TrisHCl, pH 7.5; 10% v/v glycerol; 0.1% v/v Triton X-100; 2 mM EDTA; 1 mM DTT; 1 mM
phenylmethylsulfonyl fluoride (PMSF); 10 µg/mL leupeptin; and 50 µg/mL lysozyme.
This mixture was then homogenized via mechanical lysis through sonication in 30 second
intervals for a total processing time of 5 minutes. Once the resuspension had been
homogenized, 5 mM ATP and 10 mM MgCl2 was added.
The cells were then centrifuged at 6,000 x g for 60 minutes. To the supernatant,
0.25 volumes of 50% w/v PEG 6000 in 50 mM Tris-HCl, pH 7.5, were added. This
mixture was allowed to incubate at room temperature for 30 minutes, after which it was
centrifuged at 6,000 x g for 30 minutes. The supernatant was discarded, and the pellet
was resuspended in Buffer A, which consisted of 20 mM Tris-HCl, pH 7.8; 10% v/v
glycerol; 0.2 mM EDTA; and 0.5 mM DTT.
A quaternary amine, Q-Sepharose ion exchange chromatography column was
performed in order to purify ARS875 from the rest of the cell protein. This was
performed using FPLC. The protein mixture in Buffer A was loaded onto the column and
was eluted with a linear gradient of 0 to 0.25 M Na2SO4. To perform this gradient,
Buffer B was prepared, which consisted of 20 mM Tris-HCl, pH 7.8; 10% v/v glycerol;
0.2 mM EDTA; 0.5 mM DTT; and 0.25 M Na2SO4. According to literature, elution was
expected at 0.1 M Na2SO4 [77]. Fractions were collected at 2 mL/min and UV was used
to determine fractions of interest, which were verified by SDS-PAGE.
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In an effort to clear up background protein, a size exclusion column (SEC) was
run via FPLC. Buffer for this column contained 20 mM Tris-HCl, pH 7.8; 10% v/v
glycerol; 0.2 mM EDTA; and 0.5 mM DTT. Fractions were eluted at 1 mL/min for 8 mL
fractions. Using the UV read-out of the FPLC, peaks of interest were then run on SDSPAGE gel to evaluate the presence of ARS875. Fractions containing ARS875 were then
pooled and concentrated to a final volume of 1 mL and stored in 50% glycerol at -80 °C.

2.10 Aminoacylation
To perform aminoacylation, the following were combined in an Eppendorf tube to
a total volume of 500 µL: 4,000 pmol tRNAAla; 100 µM alanine; 100 µM HEPES-KOH,
pH 7.6; 10 mM ATP; 1 mM DTT; 10 mM KCl; 20 mM MgCl2; and 1 µM ARS875. This
reaction was incubated at 37 °C for 30 minutes.
After incubation, 50 µL 3 M NaOAc, pH 5.2, was added to the reaction mixture.
The mixture was then combined with equal volume of phenol on ice for 10 minutes. The
reaction mixture was then spun in the microfuge for 5 minutes at 20,000 x g, after which
the aqueous layer was transferred to a new tube. The aqueous layer was then extracted
twice with 300 mM NaOAc, pH 5.2, and the aqueous layers were combined. This layer
was then extracted twice with an equal volume of chloroform. Finally, the aminoacylated
product was precipitated with 2.5 volumes of cold 100% ethanol.
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CHAPTER THREE

RESULTS AND DISCUSSION

3.1 Background
This study began by evaluating the results from the in vitro DNA purification
protocol to confirm the presence of the plasmid DNA containing the gene for tRNAAla
and the T7 promoter. Once this had been accomplished, a restriction enzyme digest was
performed, and a DNA agarose gel was run to confirm that complete cleavage of the
plasmid had occurred, resulting in a fragment containing only the gene for tRNAAla and
the T7 promoter. After confirmation of cleavage, several optimization trials were run for
small scale in vitro transcription to determine the best conditions with which to run the
large-scale reaction for maximum production of tRNAAla. Once optimization was
complete, a large-scale IVT reaction was performed and evaluated for the presence of
tRNAAla.
Next, after performing in vivo production of tRNAAla, acid urea gels were run to
analyze for the presence of tRNA after purification via phenol:chloroform extraction and
ethanol precipitation. Production of alanyl-tRNA synthetase was performed, along with
ion exchange and size exclusion chromatography, and these processes were analyzed via
SDS-PAGE gel to evaluate for presence of the enzyme. A comparison of the in vitro and
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in vivo methods of production was done to determine the most efficient and cost-effective
way of producing the greatest amount of tRNAAla.

3.2 in vitro DNA Purification Protocol
A large-scale DNA purification protocol was performed in order to isolate the 2.7
kb plasmid DNA from E. coli cultures grown in LB media. This isolation took place over
the course of several precipitation reactions with which the cell debris, protein, and RNA
was removed from the cell mixture. To confirm the presence of the isolated plasmid
DNA, a 1.5% DNA agarose gel using ethidium bromide as a DNA intercalating agent to
allow for visualization of the plasmid DNA band under UV light.
Interestingly, it was found that using a polyethylene glycol (PEG) precipitation
was key to isolation of the plasmid alone, as without this precipitation step small
oligonucleotide contamination persisted in the reaction mixture. The addition of 13%
PEG allowed for the solubility of the DNA to decrease and precipitate while still
effectively keeping the small oligonucleotide contamination in the aqueous phase. The
effectiveness of this precipitation reaction was tested twice, as even though the small
oligonucleotide contamination was heavily reduced after the first precipitation, some
contamination still remained. The results of this test and the DNA agarose gel showing
the isolated 2.7 kb DNA plasmid is shown in Figure 3.2.1.
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M.W.

(a)

(b)

(c)

3 kb
1 kb

500 bp

100 bp

Figure 3.2.1 Results of 1.5% agarose DNA gel run to verify the presence of the isolated
2.7 kb DNA plasmid. By using the molecular weight ladder on the left lane above, the
plasmid DNA containing the gene for tRNAAla and the T7 promoter necessary for in vitro
transcription to take place. Lane (a) presents the results of the DNA purification protocol
after only ethanol precipitation and before addition of the 13% PEG precipitation. Small
oligonucleotide contamination persisted after the purification protocol, present around
100 bp. The results of one 13% PEG precipitation reaction is shown in the lane (b).
Though the small oligonucleotide contamination had cleared considerably, there was still
the notable presence of small oligonucleotide after this first precipitation reaction. Lane
(c) shows the results of the sample undergoing a second 13% PEG precipitation reaction.
As can be seen, there is no visible small oligonucleotide contamination left, only the
presence of the 2.7 kb plasmid DNA.
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3.3 Eco31I Restriction Enzyme Digest
Once the plasmid DNA had been isolated without the smaller contamination, a
restriction enzyme digest was performed to cleave the plasmid DNA around the gene for
tRNAAla and the T7 promoter to allow for in vitro transcription. The restriction enzyme
chosen for this step was BsaI/Eco31I. This enzyme produces blunt end cuts, which
causes the T7 polymerase during in vitro transcription to fall off after producing the
tRNAAla, does not allow for any methylation of the produced tRNA, and promotes
effectiveness of translation.
Trials of the restriction enzyme digest were performed in order to test the
effectiveness of the high fidelity versus fast digest enzymes, as well as to compare the
processing time to determine the time period needed for complete cleavage of the
plasmid DNA into ~1.4 kb and ~1.2 kb fragments, the latter of which consisted of the
gene for tRNAAla and the T7 promoter. Two different DNA purification preps were
tested to ensure that the results were consistent between the two types of restriction
enzymes and processing time for the reaction.
The results of these trials were then analyzed via 1.5% agarose DNA gel with
ethidium bromide as an intercalating agent to allow for visualization under UV light.
This visualization was done to evaluate for the presence of the two separate predicted
bands, as well as determine the ratio of plasmid DNA that had not been digested. The
results of this comparison of fast digest versus high fidelity enzyme and processing time
is shown in Figure 3.3.1.
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(a)

(c)

(b)

(d)

3 kb
1.5 kb
1.2 kb

500 bp

Figure 3.3.1 The above gel is the result of the optimization trial for the BsaI/Eco31I
restriction enzyme digest comparing the activity of the high fidelity versus fast digest
enzyme, and processing times of the reaction. The molecular weight ladder is present in
the leftmost lane, allowing for a comparison of the sample lanes and verification of the
presence of the plasmid DNA fragments expected at ~1.4 kb and ~1.2 kb. The first
sample lane is the restriction enzyme digest using the high-fidelity restriction enzyme
with a processing time of 17 hours (a). To the right of this sample is the restriction
enzyme digest using the fast digest restriction enzyme with the same processing time of
17 hours (b). The next lane shows the results of the restriction enzyme digest using the
high-fidelity enzyme for a total processing time of 24 hours (c). Finally, the last sample
lane shows the results of the restriction enzyme digest performed using the fast digest
enzyme with the same processing time of 24 hours (d).
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When evaluating the results of this optimization trial for the restriction enzyme
digest, it was shown that there was no difference between the high fidelity and fast digest
versions of Eco31I. There was also shown to be no difference between the 17-hour and
20-hour processing times. All four of the lanes show complete cleavage of the plasmid
DNA, which was originally 2.7 kb, as seen by the clear presence of the fragment bands at
~1.2 kb and ~1.4 kb. Notably, the ~1.2 kb band is the fragment containing the gene of
interest and the T7 promoter, where the band at ~1.4 kb represents the rest of the plasmid
DNA. As there was no discernable difference in the performance of the different types of
restriction enzyme, nor the processing time, the reaction was considered optimized using
the fast digest Eco31I restriction enzyme digest with a processing time of 17 hours for all
further digests in preparation for in vitro transcription.

3.4 Small Scale in vitro Transcription Optimization
Several optimization steps were necessary in order to produce the most tRNAAla
in the most efficient manner. Optimization began with evaluation of the performance of
T7 polymerase that was purified via different methods. A comparison was done between
T7 purified via nickel affinity column chromatography, quaternary amine ion exchange
column, and size exclusion column by performing small scale in vitro transcription
reactions and comparing the amount of tRNAAla produced as a result. An initial
comparison of time points was also done to preemptively determine if processing time
also played a role in the effectiveness of the polymerase in production of tRNA.
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To analyze these reactions and determine the most efficient purification method,
the reactions were run on 6% urea gels which were run at 200 V for 60 minutes. The gels
were then stained with SYBR Gold dye and visualized via UV. As tRNA is
approximately 76 nucleotides in length, it was expected that the product of these
reactions would be near the bottom of the processed urea gel. The results of the
optimization for T7 purification method are seen in Figure 3.4.1.
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(a)

(b)

(c)

(d)

1.2 kb
1 kb

0.2 kb

0.1 kb

Figure 3.4.1 This 6% urea gel shows the results of the optimization of purification
methods for T7 polymerase. The molecular weight ladder is shown in the leftmost lane.
Lane (a) shows the small scale IVT reaction performed using the nickel affinity column
purified T7 polymerase with a 3-hour reaction time. Lane (b) shows the results of the
IVT reaction using the T7 polymerase further purified by ion exchange chromatography
with a 3-hour reaction time. In lane (c), T7 polymerase further purified by size exclusion
chromatography with a 3-hour IVT reaction time is shown; and in lane (d), size exclusion
purified T7 polymerase is shown with a reaction time of 5 hours to allow for a
preliminary processing time comparison.
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From the urea gel above, it is clear to see that the T7 polymerase purified by
nickel affinity column which did not undergo further purification produces the most
tRNAAla in a small scale IVT reaction. This is likely due to the fact that further
purification of the enzyme removes some important co-factor which increases the
processivity of the enzyme itself. When evaluating the differences between the 3-hour
and 5-hour reactions using the size exclusion chromatography purified enzyme, there is a
slight difference in the quantity of tRNAAla produced based on time. However, the
results of this trial needed to be verified via further testing. Based on the above results, it
was decided that the most effect means of purification for the T7 polymerase enzyme was
nickel affinity column chromatography, even though all three purification methods did
result in production of tRNAAla.
To continue optimization of the small-scale in vitro transcription reaction, further
experimentation was done to determine the ideal reaction time and concentration of T7
polymerase necessary to produce the most efficient final large-scale reaction. Small scale
reactions were done for 3, 4, and 5 hours utilizing nickel affinity purified T7 polymerase
concentrations of 5 μL/mL, 10 μL/mL, and 20 μL/mL. It was expected that an increase
in enzyme concentration would lead to an increase in production of tRNAAla, and an
increase in reaction time would allow for the transcription process to continue and for
more tRNAAla to be generated. Once again, the results of these small-scale reactions
were analyzed via 6% urea gel and stained with SYBR Gold dye. The gel was then
visualized via UV and evaluated for production. The results of this optimization test are
shown in Figure 3.4.2.
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1.2 kb
1 kb

0.2 kb

0.1 kb

Figure 3.4.2 This gel shows the results of the optimization of processing time and T7
polymerase concentration. The first three sample lanes represent a nickel affinity column
purified T7 polymerase concentration of 5 μL/mL with processing times of 3, 4, and 5
hours, respectively (a)-(c). The next three lanes contain a T7 polymerase concentration
of 10 μL/mL for processing times of 3, 4, and 5 hours (d)-(f). The last three sample lanes
contain a T7 polymerase concentration of 20 μL/mL for the same three time points of 3,
4, and 5 hours (g)-(i).
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All small scale IVT reactions in this optimization trial were successful in
producing some quantity of tRNAAla. However, it was noted that the best results from
this optimization were from the reaction with a concentration of 20 μL/mL for a 5-hour
processing time. Therefore, these conditions were selected for future optimization trials
and the eventual large-scale in vitro transcription reaction.
Small scale IVT reactions were then performed to evaluate the effect that an
increase in nucleotide and MgCl2 concentration would have on the production of
tRNAAla. It was surmised that an increase in nucleotides would allow for an increase in
product. It was also predicted that an increase in MgCl2 concentration would increase the
production of tRNAAla, as magnesium acts to stabilize DNA and RNA. Four small scale
reactions were performed with increasing concentrations of nucleotides in the amounts of
4.5 mM, 6 mM, 7.5 mM, and 9 mM. Four IVT reactions were performed with increasing
concentrations of MgCl2 in the amounts of 20 mM, 28 mM, 36 mM, and 42 mM. The
reactions were then analyzed via 6% urea gel as seen in Figure 3.4.3.
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Figure 3.4.3 This gel displays the results of the nucleotide and MgCl2 concentration
trials. Using the molecular weight ladder to the left of the gel, the presence and relative
concentration of the produced tRNAAla was analyzed. Lanes (a)-(d) show the effects of
an increase in MgCl2, with increasing concentrations of 20 mM, 28 mM, 36 mM, and 42
mM, respectively. Lanes (e)-(h) display the effects of increasing concentrations of ATP,
GTP, UTP, and CTP in the amounts of 4.5 mM, 6 mM, 7.5 mM, and 9 mM.
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According to the urea gel results, production of tRNAAla was successful in all
concentrations of MgCl2 and nucleotides. When evaluating the results of the MgCl2
increase, it is clear to see from the gel that an increase in the concentration did not lead to
an increase in produced tRNAAla from the in vitro transcription reaction. In fact, the
addition of more MgCl2 tended to have the opposite effect than anticipated, as the
quantity of tRNAAla produced decreased as the concentration of MgCl2 increased. It was
therefore determined that additional testing as far as the effect of MgCl2 increase was
warranted, as the results were inconclusive.
In contrast to the inconclusive results of the initial optimization of MgCl2
concentration, there was a notable correlation to the increase in production of tRNAAla to
the increase of nucleotide concentration as verified by the gel above. Therefore, it was
determined that an increase in nucleotides was necessary to increase the yield of the in
vitro transcription reaction.
The final step in the optimization of the small scale IVT reaction was to further
investigate the effects of an increase in MgCl2 concentration, as well as to test the effects
of an increase in GTP concentration alone. The increase in GTP was hypothesized to
increase the reaction yield, as GTP is known to be a requirement for the initiation of the
transcription process. As T7 polymerase specifically dissociates early in the transcription
process, inclusion of a higher concentration of GTP prevents the GTP in the reaction
mixture from being depleted and allows transcription to continue without being limited
by this factor. In an effort to determine if the yield of tRNAAla increased with increasing
concentration of GTP, as well as to further investigate the effects of MgCl2 concentration,
four small scale reactions were performed. Two of these reactions involved a
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concentration of 9 mM GTP, and two of the reactions contained a 12 mM concentration
of GTP. MgCl2 concentrations were tested at a standard concentration of 28 mM and 42
mM. The results of this optimization are shown in Figure 3.4.4.
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(c)

(d)
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0.1 kb

Figure 3.4.4 These are the results of the optimization for concentration of GTP and
reevaluation of MgCl2 concentration on the production of tRNAAla. Lane (a) represents a
GTP concentration of 9 mM and a MgCl2 concentration of 28 mM. Lane (b) shows the
results from the same 9 mM concentration of GTP and an increased MgCl2 concentration
of 42 mM. Lanes (c) and (d) represent an increased concentration of GTP in the amount
of 12 mM and MgCl2 concentrations of 28 mM and 42 mM, respectively.
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In all four trials for the optimization of GTP and MgCl2 there is the presence of
produced tRNAAla. It is clear to see from the results of the urea gel that an increase in the
concentration of GTP produces more tRNAAla as hypothesized. However, when
evaluating the results of the gel, the presence of increased MgCl2 leads to a decrease in
the production of tRNA. Therefore, it can be determined that increasing MgCl2 is
inhibitory to the IVT reaction.

3.5 Large Scale in vitro Transcription
As the optimization of the small-scale reactions was complete, a large-scale
production of tRNAAla took place via in vitro transcription using the optimized
parameters noted above in Section 3.4. Once the reaction was completed, the results
were run on four 6% urea gels. UV shadowing technique was used to excise the gel
slices containing the produced tRNAAla, an example of which is shown in Figure 3.5.1.
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Figure 3.5.1 This image shows an example of the technique of UV shadowing. The
formamide dye used in the 6% urea gel presents as two separate bands when the sample
is run. The produced tRNAAla is present between the two separate bands of dye and
presents as a shadow under UV light. The position of the produced tRNAAla is then
marked on the gel and the shadow band is excised and processed to elute the tRNAAla.
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Once the band had been excised from the four urea gels, it was allowed to soak in
buffer for one, two, and three days to allow for passive elution. These samples were then
run on 6% urea gel to evaluate for the presence of tRNAAla in the buffer solution. The
results of this gel are shown in Figure 3.5.2.
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(a)
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0.2 kb

0.1 kb

Figure 3.5.2 This gel shows the results of the passive elution performed to extract the
produced tRNAAla from the excised gel slices after the large scale IVT reaction. Lanes
(a)-(c) show the result of the elution procedure one, two, and three days after changing
the buffer solution.
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As evidenced from the above figure, tRNAAla was successfully eluted from the
passive elution process after all three days. However, the amount of tRNAAla that eluted
from the buffer soak on day three was a negligible amount. Therefore, it was seen that
after both the first and second day of passive elution, a large amount of tRNAAla was able
to be recovered from the gel excision slices. Quantification of the produced tRNAAla
concluded that a total of 4 mg of tRNAAla was recovered from the large-scale in vitro
transcription reaction.

3.6 in vivo Production of tRNAAla
In an effort to provide a comparison between the in vitro and in vivo methods of
tRNAAla production, in vivo production was performed. To analyze the results of this
reaction, a 6% acid urea gel was run for an average of three hours, ensuring to keep
temperature of the gel box between 8 °C and 12 °C. The gel was then stained overnight,
de-stained, and visualized to determine if the in vivo reaction successfully produced
tRNAAla. Controls of bulk peptidyl-tRNA and cleaved peptidyl-tRNA were run to verify
the positioning and molecular weight of the produced tRNAAla. It was hypothesized that
if the in vivo production was successful, the positioning of the sample bands should be
the same molecular weight as that of the cleaved peptidyl-tRNA. Figure 3.6.1 shows the
results of this experiment.
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(a)

(b)

(c)

(d)

tRNAAla

Figure 3.6.1 This gel is a 6% acid urea gel which was run to evaluate for the presence of
produced tRNAAla from the in vivo reaction. Lane (a) represents a control of bulk
peptidyl-tRNA. Lane (b) is the control of cleaved peptidyl-tRNA. Lanes (c)-(d) are
samples containing the reaction mixture from the in vivo production.
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The 6% acid urea gel run on the reaction samples after the in vivo production
show that the product of this reaction has similar molecular weight to that of the cleaved
peptidyl-tRNA. This is verification that tRNAAla is being produced from the in vivo
reaction. According to literature provided for this process, the yield of tRNAAla is ~80%
of the total tRNA as consideration must be taken for endogenous tRNA species. Thus, a
total of approximately 8 mg of tRNAAla was produced from the in vivo reaction from an
initial 1 L culture.

3.7 in vivo Production of Alanyl-tRNA Synthetase
The in vivo production of Alanyl-tRNA synthetase (ARS875) was performed. In
order to purify the enzyme, first a quaternary amine ion exchange column, or Q-column,
was run. It was expected that ARS875 would elute from the column at around 40%
Na2SO4. Figure 3.7.1 shows the UV read-out of the ion exchange column. The fractions
surrounding the peaks were isolated and run on an SDS-PAGE gel in order to analyze
these fractions for the presence of ARS875. The results of this SDS-PAGE gel are shown
in Figure 3.7.2.
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Figure 3.7.1 This chromatogram is taken from the UV read-out (A280) of the fast protein
liquid chromatography instrument used to run the quaternary amine ion exchange column
to purify ARS875. The peaks represent the areas of column elution containing protein.
Fraction numbers are denoted on the chromatogram. Samples surrounding key peaks in
the chromatogram were isolated and run on SDS-PAGE gel.
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Figure 3.7.2 Results of SDS-PAGE gel which was run on the fractions isolated from the
Q-column. As ARS875 is a 95 kDa enzyme, a band near the 100 kDa marker on the
protein ladder was expected. This band can be seen on the above gel in fractions #29 and
#30.
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As ARS875 was found in fractions #29 through #30 of the Q-column, which were
pooled and concentrated. As expected, this elution of ARS875 occurred around 40%
Na2SO4 [77]. However, as there still remained background protein present in the sample,
a size exclusion column was performed in an effort to purify ARS875 further. The
results of the size exclusion column chromatogram are shown in Figure 3.7.3. It was
expected that the elution of the 95 kDa enzyme would occur between fractions #25 and
#40, based on established lab standards. An SDS-PAGE gel was run on peaks
surrounding these areas of interest, and the results of that gel are shown in Figure 3.7.4.
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Figure 3.7.3 This chromatogram shows the UV read-out (A280) from the FPLC after
performing size exclusion chromatography. Fraction numbers are denoted below the
chromatogram.
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Figure 3.7.4 This is the result of the SDS-PAGE gel run on the fractions of interest from
the UV read-out of the FPLC after the size exclusion column was performed. In order to
run a positive control, the concentrated sample that was subjected to the column was run
in the first sample column so that the fraction samples could be compared to a standard
where ARS875 was known to be present. The fraction numbers of the samples run from
the size exclusion column are denoted above the lanes of the gel.
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ARS875 was found to be in fractions surrounding #30 from the size exclusion
column. Fractions #30 through #33 were then pooled and concentrated to a volume of 1
mL for further use in the aminoacylation procedure. After quantification, it was found
that approximately 2 mg of ARS875 was produced from a 1 L culture and purification of
the enzyme.
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CHAPTER FOUR

CONCLUSIONS AND FUTURE WORK

4.1 Conclusions
Antibiotic resistance is a growing challenge in the modern medical community.
Though there have been many classes of antibiotics developed since their origin in the
1920s, there has been an increasing lull in discovery of new classes with new
mechanisms of action. The treatment of infectious diseases with antibiotics was once
thought to be a course of action to eradicate these diseases altogether, but as more
bacteria are becoming resistant to these drugs, it has become apparent that the answer to
the spread of infectious diseases is not so simple. As bacteria have been able to
incorporate mechanisms of resistance to all seven of the major classes of antibiotics, it is
imperative that novel antibacterial targets be discovered, and potential new mechanisms
of drug action be explored in the scientific and medical community.
As Pth1 represents one such a novel target, the exploration of the mechanism of
action with which this enzyme functions is of utmost importance. In order to evaluate the
potential of the Pth1 enzyme as an antibacterial target, a better understanding of the
binding interactions between the enzyme and its substrate is necessary. The challenge in
this lies in the fact that no high-resolution crystal structure for Pth1 in complex with
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peptidyl-tRNA exists. As the structural make-up of tRNA depends on the specific amino
acid with which it correlates, the first step in achieving this high-resolution crystal
structure is obtaining amino acid specific tRNA through a reliable means of production
which generates a high yield of the molecule.
The goal of producing tRNAAla has been achieved through both in vitro and in
vivo methods to allow for a comparison of the methods of production and evaluation of
their efficiency and yield. By comparing the results of these methods of production, the
generation of this molecule can be optimized for maximum yield in relation to the
complexity and difficulty of the particular method. As this study resulted in a yield of 4
mg of tRNAAla via the in vitro method and 10 mg of tRNAAla through use of the in vivo
method of production, it can be concluded that not only does the in vivo method produce
more tRNAAla per 1 L bacterial culture, but also that the in vivo method produces
tRNAAla more reliably, less expensively, and with less optimization needed. Use of this
method is the best course of action for production of amino acid specific tRNA molecules
and should be used to further study the interactions between peptidyl-tRNA and Pth1.
The in vivo method of production for alanyl-tRNA synthetase also provides a
straightforward and reliable method of production for this enzyme. As aminoacylation of
the generated tRNAAla is necessary for production of a homogeneous substrate in order to
create a high-resolution crystal structure of the bound-state, preparation of a large
quantity of this enzyme will be beneficial towards not only achieving that crystal
structure, but also for any potential binding and kinetics studies used in the future. As the
wildtype of this enzyme, ARS875, can be produced inexpensively and without difficulty
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through in vivo production and subsequent purification, generation of aminoacylated
tRNAAla can be achieved readily for this future work.

4.2 Future Work
As both tRNAAla and alanyl-tRNA synthetase can be readily prepared via the in
vivo method of production, first verification of the effectiveness of the aminoacylation
process should be evaluated. Ideally, this could be achieved via the use of mass
spectrometry and comparison of the M+ peaks in the generated spectra. By examining
the amount of tRNAAla that undergoes aminoacylation, a better understanding of the
effectiveness of the ARS875 enzyme in performing this function can be determined.
Once aminoacylation of tRNAAla can be determined, quantitative production of
peptidyl-tRNAAla can occur. As Pth1 requires peptidyl-tRNA and not just Ala-tRNAAla
to function, the production of peptidyl-tRNAAla will allow for the activity of the Pth1
enzyme to be tested with tRNAAla generated via the in vivo method of production. The
activity of the enzyme can be verified via acid urea gel and confirmation of cleavage of
the ester bond by analyzing for a shift in molecular weight between the cleaved and
uncleaved samples of peptidyl-tRNAAla.
Furthermore, it would be beneficial to study the kinetics of the generated
peptidyl-tRNAAla structure with the Pth1 enzyme. The in vivo method of tRNAAla
production is successful in generating high yields of tRNA; therefore, several studies
could be performed in order to better understand the kinetic properties of the enzymesubstrate complex. As initial kinetics studies have been done with the Pth1 enzyme in
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complex with bulk peptidyl-tRNA [80], it would be important to be able to determine if
those kinetic parameters persisted with the in vivo generated peptidyl-tRNAAla. Of
particular interest would be the validation of previously determined KM, enzyme
saturation, and potential concentration studies to optimize the enzyme-substrate ratios for
ideal conditions in order to more easily achieve a bound-state crystal structure.
After it has been verified that the Pth1 enzyme exhibits activity in the presence of
peptidyl-tRNAAla, production of a high-resolution crystal structure of the enzymesubstrate complex should be the next major goal of this project. Once the enzymesubstrate complex is crystallized, production of this structure could occur via x-ray
crystallography or NMR. This will allow for elucidation of the binding interactions
necessary for Pth1 to function in cleaving the ester bond between the tRNAAla molecule
and the nascent peptide chain. With further knowledge of these necessary interactions,
small molecules possessing the same molecular characteristics can be tested as potential
inhibitors of the enzyme’s activity.
With a better understanding of the electrostatic and hydrophobic interactions
present near the key residue binding site of Pth1 obtained through formation of a boundstate high-resolution crystal structure, computational studies of the enzyme-substrate
complex will be more meaningful. The first step in this would be molecular docking
studies. Though molecular docking has been performed on the apo structure previously,
docking to this structure does not correlate to experimental binding. Achievement of a
bound-state, high-resolution crystal structure will allow the results of such computational
studies to produce more realistic and relevant results that had previously been
unattainable. As a high-resolution crystal structure of the bound and active form of the
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enzyme would also allow for discernment of the overall shape of the binding site, this
knowledge would be greatly beneficial for successful docking results. The bound-state
crystal structure would be screened against several small molecule databases, such as the
zinc database, Specs database, NCI Open database, and World Drug Index. Molecular
docking studies would be used to approximate ΔG values associated with interactions
between the small molecules and the binding site. Screening would provide information
as to what small molecules produced the most favorable interactions through binding and
allow for a potential list of small molecule inhibitors to be compiled.
Once the potential inhibitors can be determined via docking, molecular dynamics
could be performed in order to examine the behavior of these small molecules in an
environment which would simulate that of biological conditions over time and different
temperatures. These simulations would allow for evaluation of movement of the small
molecules inside the binding pocket of the active site. While gradual shifts of the
screened ligands within the binding site are natural as the ligand achieves optimal
positioning, any movement outside of the binding pocket or away from the key residues
would effectively negate the possibility of a small molecule to be a successful inhibitor.
For a ligand to be considered a potential inhibitor, it must retain interactions with the key
residues of the binding site. Performance of molecular dynamics studies would allow for
the list of potential inhibitors to be narrowed down considerably to a few promising
compounds.
Once computational studies have been conducted, in-lab screening of potential
inhibitors can be performed. This can be done by comparing the percent cleavage of
peptidyl-tRNAAla to that of both uncleaved peptidyl-tRNAAla and peptidyl-tRNAAla that
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has been subjected to cleavage by Pth1. Verification of this process can be done via acid
urea gel and comparison to the positive and negative controls.
As the rise of antibiotic resistance has resulted in a growing crisis worldwide,
identification of new targets and development of new classes of antibiotics is critical.
Peptidyl-tRNA hydrolase I represents a promising antibacterial target due to its essential
function in bacteria, lack of homology in eukaryotes, and high degree of sequence
similarity between bacterial species. This study provides a method for advanced
homogeneous substrate production, thereby granting the ability to achieve a bound-state
structure of the enzyme-substrate complex. Generation of a high-resolution crystal
structure of the bound-state would pave the way towards exploring this target further and
potential discovery of a new antibiotic class, leading towards improvement in global
health and advancement in modern medicine.
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